

# Quantifying the impact of quarantine duration on COVID-19 transmission \*

Peter Ashcroft<sup>1\*</sup>, Sonja Lehtinen<sup>1</sup>, Daniel C. Angst<sup>1</sup>, Nicola Low<sup>2</sup>, and Sebastian Bonhoeffer<sup>1</sup>

<sup>1</sup>*Institute of Integrative Biology, ETH Zurich, Switzerland*, <sup>2</sup>*Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland*

---

## Abstract

The numbers of confirmed cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are increasing in many places. Consequently, the number of individuals placed into quarantine is increasing too. The large number of individuals in quarantine has high societal and economical costs. There is ongoing debate about the duration of quarantine, particularly since the fraction of individuals in quarantine who eventually test positive is perceived as being low. We present a mathematical model that uses empirically determined distributions of incubation period, infectivity, and generation time to quantify how the duration of quarantine affects transmission. We use this model to examine two quarantine scenarios: traced contacts of confirmed SARS-CoV-2 cases and returning travellers. We quantify the impact of shortening the quarantine duration in terms of prevented transmission and the ratio of prevented transmission to days spent in quarantine. We also consider the impact of i) test-and-release strategies; ii) reinforced hygiene measures upon release after a negative test; iii) the development of symptoms during quarantine; iv) the relationship between quarantine duration and adherence; and v) the fraction of individuals in quarantine that are infected. When considering the ratio of prevented transmission to days spent in quarantine, we find that the diminishing impact of longer quarantine on transmission prevention may support a quarantine duration below 10 days. This ratio can be increased by implementing a test-and-release strategy, and this can be even further strengthened by reinforced hygiene measures post-release. We also find that unless a test-and-release strategy is considered, the fraction of individuals in quarantine that are infected does not affect the optimal duration of quarantine under our utility metric. Ultimately, we show that there are quarantine strategies based on a test-and-release protocol that, from an epidemiological viewpoint, perform almost as well as the standard 10 day quarantine, but with a lower cost in terms of person days spent in quarantine. This applies to both travellers and contacts, but the specifics depend on the context.

---

## 1 Introduction

Quarantining individuals with high risk of recent infection is one of the pillars of the non-pharmaceutical interventions to control the ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic (Kucharski et al., 2020). Owing to

---

\*Code is publicly available at <http://github.com/ashcroftp>. Current version: 02 October, 2020; Corresponding authors: [peter.ashcroft@env.ethz.ch](mailto:peter.ashcroft@env.ethz.ch), [seb@env.ethz.ch](mailto:seb@env.ethz.ch)

39 the large fraction of transmission of SARS-CoV-2 that is pre-symptomatic or asymp-  
40 tomatic (Ashcroft et al., 2020; Buitrago-Garcia et al., 2020; Ferretti et al., 2020a; He  
41 et al., 2020), quarantine can prevent a substantial fraction of onward transmission that  
42 would not be detected otherwise. In mathematical modelling studies, it was estimated  
43 that thermal screening at airports would allow more than 50% of infected travellers to  
44 enter the general population (Quilty et al., 2020a; Gostic et al., 2020), which could have  
45 been prevented by mandatory quarantine. With the high or increasing case numbers  
46 that are observed in many places around the globe, however, more and more people  
47 are being placed into quarantine.

48 There is ongoing public debate about the appropriateness of quarantine and its du-  
49 ration. Quarantine lowers onward transmission in two ways: first, preventing trans-  
50 mission prior to symptom onset (with the assumption that symptomatic individuals  
51 will isolate) and decreasing overall transmission from persistently asymptomatic in-  
52 dividuals. The appropriate length of quarantine thus depends on both incubation  
53 period and the temporal profile of infectiousness. In theory, quarantine periods could  
54 be avoided altogether through widespread and regular testing programmes, but the  
55 low sensitivity of reverse transcriptase PCR (RT-PCR) tests, particularly in early in-  
56 fection (Kucirka et al., 2020), and limitations on testing capacity in most countries,  
57 preclude this approach. Quarantine has high economic, societal and psychological  
58 costs (Nicola et al., 2020; Brooks et al., 2020). It restricts individual freedoms (Parmet  
59 & Sinha, 2020), although the level of restriction imposed is generally judged to be  
60 proportionate, given the severity of coronavirus disease 2019 (COVID-19). The low  
61 number of individuals placed in quarantine that turn out to be infected is another  
62 argument that is given against quarantine.

63 Individuals are generally placed into quarantine for one of two reasons: either  
64 they have been identified as a recent close contact of a confirmed SARS-CoV-2 case by  
65 contact tracing, or they have returned from recent travel to a high-risk area with levels  
66 of community transmission that are higher than in the home country (WHO, 2020).  
67 These groups of quarantined individuals differ in two important ways: compared  
68 with traced contacts, travel returners may have lower probability of being infected  
69 and have less precise information about the likely time of exposure. This raises the  
70 question whether the duration of quarantine should be the same for these two groups  
71 of individuals.

72 To our knowledge there are no clinical trials published that directly assess the im-  
73 pact of duration of quarantine on SARS-CoV-2 transmission (Nussbaumer-Streit et al.,  
74 2020). In this study, we present a mathematical model that allows quantification of the  
75 effects of changing quarantine duration. We use the distributions of incubation time  
76 (time from infection to onset of symptoms), infectivity (infectiousness as a function of  
77 days since symptom onset), and generation time (difference of time points of infection

78 between infector and infectee). These distributions have been estimated by Ferretti  
79 et al. (2020a), combining multiple empirical studies of documented transmission pairs  
80 (Ferretti et al., 2020b; Xia et al., 2020; Cheng et al., 2020; He et al., 2020).

81 Using the model, we explore the effect of duration of quarantine for both traced  
82 contacts of confirmed SARS-CoV-2 cases and for returning travellers on the fraction  
83 of prevented onward transmission. We assess the effects of test-and-release strategies  
84 and the time delay between test and result. These considerations are particularly im-  
85 portant given that multiple testing has been shown to be of little benefit (Clifford et al.,  
86 2020). We also address the role of pre-symptomatic patients becoming symptomatic  
87 and therefore being isolated independent of quarantine. Furthermore, as one of the ar-  
88 guments for shortening the duration of quarantine is to increase the number of people  
89 complying with the recommendation, we investigate by how much adherence needs  
90 to increase to offset the increased transmission due to earlier release from quarantine.  
91 Finally, we assess the role of reinforced individual-level prevention measures, such as  
92 mask wearing, for those released early from quarantine.


93 Making policy decisions about the duration of quarantine fundamentally requires  
94 specifying how the effectiveness of quarantine relates to its costs. The effectiveness  
95 can be measured in terms of the overall reduction of transmission, while economical,  
96 societal, and individual costs are likely a function the days spent in quarantine. In  
97 addition to the epidemiological outcome, which considers only the reduction in trans-  
98 mission, we also present results based on the ratio of transmission prevented to the  
99 average number of days spent in quarantine.

## 100 2 Methods


### 101 2.1 Quantifying the benefit of quarantine

102 Our primary goal is to quantify how much transmission is prevented by quarantining  
103 individuals who have been potentially exposed to SARS-CoV-2. To achieve this we  
104 need to know the time at which the individual was exposed ( $t_E$ ), as well as when they  
105 enter ( $t_Q$ ) and are released from ( $t_R$ ) quarantine (Fig. 1A). The timing of onward trans-  
106 mission (Fig. 1B) is determined by: the generation time distribution describing the  
107 time interval between the infection of an infector and infectee (Fig. 2A); the infectivity  
108 profile describing the time interval between the onset of symptoms in the infector and  
109 infection of the infectee (Fig. 2B); and the incubation period distribution describing  
110 the time between the infection of an individual and the onset of their symptoms (Fig.  
111 2C). A detailed discussion about the relationships between these distributions can be  
112 found in Lehtinen et al. (2020).

113 Ultimately, the fraction of transmission prevented by the quarantine of an infected  
114 individual is the area under the generation time distribution  $q(t)$  [Fig. 2A] (or alterna-



**Fig. 1** A) The timeline of quarantine. Individuals are exposed to an infector at time  $t_E$ , and then quarantined at time  $t_Q$ . Under the standard quarantine protocol, this individual is quarantined until time  $t_R$ , and no onward transmission is assumed to occur during this time. Under the test-and-release protocol, quarantined individuals are tested at time  $t_T$  and released at time  $t_{R-}$  if they receive a negative test result. Otherwise the individual is isolated until  $t_{R+}$ . B) The timeline of infection. Here we illustrate the relationships between incubation periods, generation time, serial interval, and infection relative to symptom onset for an infector–infectee transmission pair.



**Fig. 2** A) The generation time distribution  $[q(t)]$  follows a Weibull distribution (Ferretti et al., 2020a). B) The infectivity profile follows a shifted Student's  $t$ -distribution (Ferretti et al., 2020a). C) The distribution of incubation times follows a log-normal distribution (Li et al., 2020).

115 tively under the infectivity profile, Fig. 2B) between the times at which the individual  
116 enters and leaves quarantine (Grantz et al., 2020). Here we use the generation time  
117 distribution, such that the fraction of transmission prevented is

$$F = \int_{t_Q}^{t_R} dt' q(t' - t_E). \quad (1)$$

## 118 2.2 Traced contacts versus returning travellers

119 We consider the scenarios of a traced contact and a returning traveller differently,  
120 because the values of  $t_E$ ,  $t_Q$ , and  $t_R$  are implemented differently in each case.

### 121 Traced contacts

122 Following a positive test result, a confirmed index case has their recent close contacts  
123 traced. From contact tracing interviews, we know when these traced contacts were  
124 last exposed to the index case ( $t_E$ ) relative to the symptom onset of the index case  
125 ( $t = 0$ ). The contacts are then placed into quarantine at time  $t_Q = \Delta_Q$ , where  $\Delta_Q$  is  
126 the sum of the delay to the index case receiving a positive test result after developing  
127 symptoms and the further delay to tracing the contacts. Under the standard quaran-  
128 tine procedure, the traced contacts are quarantined until day  $t_R = t_E + n$ , i.e. they  
129 are quarantined until  $n$  days after their last exposure. Note that the time spent in  
130 quarantine is  $t_E + n - \Delta_Q$ , which is shorter than  $n$ .

### 131 Returning travellers

132 Unlike our traced contacts, we do not know when travellers were (potentially) ex-  
133 posed. This means that quarantine starts from the date that they return ( $t_Q = 0$ ) and  
134 lasts for  $n$  days until time  $t_R = n$ . For simplicity, we assume a traveller was infected  
135 at some time over a multi-day travel period  $-y \leq t_E \leq 0$ , where  $y$  is the duration  
136 of travel. For each exposure time  $t_E$ , we compute the fraction of *local* transmission  
137 that would be prevented by quarantine and then compute the average over the travel  
138 duration:

$$F_{\text{local}}(n) = \langle F(n)/F(\infty) \rangle_y, \quad (2)$$

139 where  $F(n)$  is given by Eq. (1) and  $\langle \cdot \rangle_y$  represents the average over the different expo-  
140 sure times  $-y \leq t_E \leq 0$ .

## 141 2.3 Fraction of individuals in quarantine that are infected

142 Quarantine is applied pre-emptively, such that we do not know the infection status of  
143 individuals when they enter quarantine. If only a fraction  $s$  of the individuals placed

144 in quarantine are infected, then the average reduction in transmission across all indi-  
145 viduals in quarantine is  $sF$ .

## 146 2.4 Test-and-release

147 The test-and-release strategy uses virological testing during quarantine to release in-  
148 dividuals with a negative test result and to place those with a positive test result into  
149 isolation. As illustrated in Fig. 1A, a test is issued at time  $t_T \geq t_Q$ . If the test is neg-  
150 ative, the individual is released when the test result arrives at time  $t_{R-}$ . Otherwise,  
151 the individual remains in isolation until time  $t_{R+}$ . One challenge with this strategy is  
152 the high probability of a false-negative RT-PCR test result (i.e. an infected individual  
153 is prematurely released into the community). As reported by Kucirka et al. (2020), the  
154 false-negative rate is 100% on days 0 and 1 post infection, falling to 67% (day 4), 38%  
155 (day 5), 25% (day 6), 21% (day 7), 20% (day 8), and 21% (day 9), before rising to 66% on  
156 day 21. We label this function  $f(x)$ , the false-negative probability on day  $x$  after infec-  
157 tion. The fraction of transmission prevented by quarantine under the test-and-release  
158 strategy is:

$$F_{\text{test}} = \int_{t_Q}^{t_{R-}} dt' q(t' - t_E) + [1 - f(t_T - t_E)] \int_{t_{R-}}^{t_{R+}} dt' q(t' - t_E), \quad (3)$$

159 where the first term captures that all individuals are quarantined until at least the test  
160 result day  $t_{R-}$ , and the second term accounts for transmission prevented by remain-  
161 ing in quarantine until  $t_{R+}$  following a positive test. Again Eq. (3) is conditional on  
162 the quarantined individual being infected, and the average effect across all quaran-  
163 tined individuals is  $sF_{\text{test}}$ , where  $s$  is the fraction of individuals in quarantine that are  
164 infected.

## 165 2.5 Reinforced prevention measures after early release

166 We further consider the possibility that individuals released after a negative test are  
167 asked to strengthen strict hygiene, mask wearing, and social distancing protocols until  
168  $t_{R+}$ . We assume that these practices reduce transmission by a fraction  $r$ , such that the  
169 onward transmission prevented by quarantining an infected individual is

$$F_{\text{reduced}} = F_{\text{test}} + rf(t_T - t_E) \int_{t_{R-}}^{t_{R+}} dt' q(t' - t_E), \quad (4)$$

170 where the extra term is the transmission prevented by the reinforced prevention mea-  
171 sures when an infected individual is prematurely released from quarantine.

## 172 2.6 Transmission reduction versus days spent in quarantine

173 One possible metric to relate the effectiveness of quarantine to its negative impact on  
174 society is to consider the ratio between the amount of overall transmission prevented  
175 and the number of person days spent in quarantine. We refer to this ratio as the utility  
176 of quarantine. Concretely, for an efficacy  $F$ , fraction of individuals in quarantine that  
177 are infected  $s$ , and average time spent in quarantine  $T$ , we define the utility as

$$U = \frac{sF}{T}. \quad (5)$$

## 178 2.7 Adherence to quarantine

179 For a quarantine duration of  $n$  days, a fraction  $\alpha(n)$  of individuals will adhere to the  
180 strategy, while a fraction  $1 - \alpha(n)$  will ignore the guideline. The fraction of transmis-  
181 sion prevented due to quarantine is  $s\alpha(n)F(n)$ . Again  $s$  is the fraction of individuals  
182 in quarantine that are infected, which we assume is independent of  $n$ . We expect  $\alpha(n)$   
183 to be a decreasing function of  $n$ , i.e. longer quarantines have a lower adherence. For  
184 two quarantine strategies with durations  $n$  and  $n'$  to have the same overall efficacy,  
185 the adherences must satisfy  $s\alpha(n)F(n) = s\alpha(n')F(n')$ , or

$$\frac{\alpha(n')}{\alpha(n)} = \frac{F(n)}{F(n')}. \quad (6)$$

186 In other words, the change in the fraction of transmission prevented by quarantine  
187 must be compensated by an inverse change in the adherence. Unless otherwise stated,  
188 we assume 100% adherence.

## 189 2.8 Persistently asymptomatic infections

190 If an individual develops symptoms and ultimately tests positive while in quaran-  
191 tine, we can remove them from the population as they would have to isolate them-  
192 selves. Importantly, this individual would be removed from the population regardless  
193 of quarantine, so the reduction of cases due to their isolation should not be counted  
194 towards the efficacy of quarantine.

195 Let  $a$  be the fraction of asymptomatic cases, who will be quarantined using the  
196 standard strategy from time  $t_Q$  until  $t_R$ . We assume that the symptomatic cases would  
197 anyway be isolated once they develop symptoms (at time  $t_S$  as described by the incu-  
198 bation period distribution, Fig. 2C), so these individuals are effectively quarantined  
199 until  $\min(t_R, t_S)$ . We further assume equal transmissibility of persistently asymp-  
200 tomatic and symptomatic infections and that both are described by the same gen-  
201 eration time distribution. This assumption might be an overestimate as onward trans-  
202 mission from persistently asymptomatic cases is less than onward transmission from

203 symptomatic cases (Buitrago-Garcia et al., 2020). For each traced contact who is put  
204 into quarantine, the fraction of infections that would be prevented by quarantine is

$$F(n, a) = a \int_{t_Q}^{t_R} dt' q(t' - t_E) + (1 - a) \int_{t_Q}^{\min(t_R, t_S)} dt' q(t' - t_E). \quad (7)$$

205 Unless otherwise stated, we assume  $a = 1$ .

## 206 **2.9 Interactive app**

207 To complement the results in this manuscript, and to allow readers to investigate dif-  
208 ferent quarantine scenarios, we have developed an online interactive application. This  
209 can be found on the *CH Covid-19 Dashboard* at <https://ibz-shiny.ethz.ch/covidDashboard/>.

## 210 **3 Results**

### 211 **3.1 Quarantining traced contacts of confirmed SARS-CoV-2 cases**


212 Any shortening of a traced contact's quarantine duration will lead to an increase in  
213 transmission from that individual, but the degree of increase depends on the extent  
214 of the shortening. The expected onward transmission (from an infected contact) that  
215 is prevented by quarantine [ $F$ ; Eq. (1)] shows the diminishing return of increasing  
216 the quarantine duration (Fig. 3A). Furthermore, as the time delay to quarantine ( $\Delta_Q$ )  
217 increases, the maximum efficacy of quarantine is reduced (because infected contacts  
218 have already transmitted before being quarantined). If the duration of quarantine is  
219 longer than 10 days, then little can be gained in terms of prevention by quarantining  
220 for longer, but reducing the delay to starting quarantine does lead to increased efficacy.

221 Note that we have assumed that the contact was infected at the last time of ex-  
222 posure. If there have been multiple contacts between them and the index case, then  
223 transmission may have occurred earlier and we would overestimate the efficacy of  
224 quarantine.

225 The utility of the quarantine strategy, as defined in Eq. (5), is

$$U(n) = \frac{sF(n)}{t_E + n - \Delta_Q}, \quad (8)$$

226 which depends on the fraction of individuals in quarantine that are infected,  $s$ . How-  
227 ever, comparing two different quarantine durations  $n$  and  $n'$  through their relative  
228 utility, i.e.  $U(n')/U(n)$ , eliminates this dependence on  $s$ . Therefore, the argument that  
229 we should shorten quarantine because of the low probability of quarantined individ-  
230 uals being infected is misguided in this situation. By calculating the relative utility,  
231 we observe that there is an optimal strategy which maximises the ratio between the



**Fig. 3** A) The fraction of total onward transmission per quarantined infected contact that is prevented by quarantine [Eq. (1)]. B) The relative utility of different quarantine durations ( $x$ -axis) compared to  $n = 10$  days, i.e.  $U(n')/U(10)$  [utility as defined Eq. (8)]. Colours represent the delay to starting quarantine,  $\Delta_Q$ . We use  $t_E = 0$ , which from the infectivity profile is the mean infection time of contacts if the index case develops symptoms at  $t = 0$ .

232 fraction of transmission prevented and the number of days spent in quarantine (Fig.  
 233 3B). This would be a duration of six to eight days, depending on the delay to starting  
 234 quarantine  $\Delta_Q$ .


### 235 Test-and-release strategy

236 Quarantined individuals are tested  $x$  days after exposure and released if the test result  
 237 is negative. As above, quarantine begins at time  $t_Q = \Delta_Q$ . The test is conducted at  
 238  $t_T = t_E + x$ , and the result is received after a delay  $\Delta_T$  at time  $t_{R^-} = t_T + \Delta_T$ . Indi-  
 239 viduals with a negative test result are released, otherwise they remain in quarantine  
 240 until time  $t_{R^+} = t_E + n$ . We here assume that  $n$  is large enough such that negligible  
 241 transmission would occur after this period.

242 For  $n = 10$ ,  $\Delta_Q = 3$ , and  $t_E = 0$ , standard quarantine (without testing) would  
 243 prevent 90.2% of onward transmission from an infected traced contact. This repre-  
 244 sents the maximum attainable efficacy: the onward transmission prevented under a  
 245 test-and-release strategy will always be below this level (Fig. 4A). This is because  
 246 of the chance of prematurely releasing an infectious individual who received a false-  
 247 negative test result. On the other hand, the test-and-release strategy always performs  
 248 better than not testing if the release time is the same as the quarantine duration (grey  
 249 line in Fig. 4A). Hence, these scenarios provide upper and lower bounds for the ef-  
 250 ficacy of the test-and-release strategy. The efficacy of the test-and-release strategy in-  
 251 creases if we test later in quarantine, because we not only increase the duration of

252 quarantine but also reduce the false-negative probability.

253 Current laboratory-based RT-PCR tests have a median turnaround of 24-48 hours.  
 254 This delay is primarily operational, and so could be reduced by increasing test through-  
 255 put. There are more rapid antigen-detection tests which can provide same day results,  
 256 but with lower sensitivity and specificity compared to RT-PCR tests (Guglielmi, 2020).  
 257 Here we assume that tests have the same sensitivity and specificity regardless of the  
 258 delay to result. Comparing to a test with delay  $\Delta_T = 2$  days, we observe that using a  
 259 rapid test ( $\Delta_T = 0$ ) can reduce the quarantine duration of individuals with a negative  
 260 test result by one day while maintaining the same efficacy (Fig. 4A): the extra accu-  
 261 racy gained by waiting one extra day until testing balances the increased transmission  
 262 caused by reducing the duration. E.g., a rapid test on day six has roughly the same  
 263 efficacy (80.5%) as testing on day five and releasing on day seven (82.4%), while short-  
 264 ening the quarantine duration of individuals with a negative test result from seven to  
 265 six days. Note that



**Fig. 4** A) The impact of the test-and-release quarantine strategy, in terms of what fraction of total onward transmission per infected traced contact is prevented by quarantine [ $F_{\text{test}}$ ; Eq. (3)]. The grey lines represent the upper and lower bounds for the fraction of transmission that can be prevented by quarantine without testing [ $F$ ; Eq. (1)]. B) The relative utility of different test-and-release quarantine durations compared to standard quarantine with duration  $n = 10$  days, i.e.  $U_{\text{test}}(n', x)/U(10)$  [Eq. (9)]. The grey curve is the relative utility of standard quarantine without testing. In both panels we use  $t_E = 0$ , which from the infectivity profile is the mean infection time of contacts if the index case develops symptoms at  $t = 0$ , and  $\Delta_Q = 3$  as the delay until quarantine begins. Individuals are tested on day  $t_T = x$  after exposure and released on day  $x + \Delta_T$  ( $x$ -axis) if negative (colour corresponds to  $\Delta_T$ ). Positive testing individuals are released at day  $n' = 10$ . We assume that the fraction of individuals in quarantine that are infected is  $s = 0.1$ , and that there are no false-positive test results. Dashed lines in both panels assume the released individuals have a 50% reduced transmission ( $r = 0.5$ ) due to reinforced hygiene and social distancing measures [Eq. (4)].

266 The function  $F_{\text{test}}$  shown in Fig. 4A describes only the epidemiological benefit

267 of quarantine. The average time spent in quarantine will be  $t_E + x + \Delta_T - \Delta_Q +$   
268  $s[1 - f(x)](n - x - \Delta_T)$ , where only positive cases  $s$  have the ability to return a pos-  
269 itive test and remain in quarantine (i.e. we assume there are no false-positive test re-  
270 sults). Hence the utility of the test-and-release strategy, using the definition in Eq. (5),  
271 is

$$U_{\text{test}}(n, x) = \frac{sF_{\text{test}}}{t_E + x + \Delta_T - \Delta_Q + s[1 - f(x)](n - x - \Delta_T)}. \quad (9)$$


272 We can now compare the test-and-release strategy with standard quarantine of dura-  
273 tion  $n = 10$  days using the relative utility  $U_{\text{test}}(n', x)/U(n)$ , which now depends on  $s$ .  
274 Based on this metric, we see that testing-and-releasing before the end of the standard  
275 quarantine period increases the utility (Fig. 4B). Testing on day five and releasing on  
276 day seven (assuming a delay  $\Delta_T = 2$  days between the test and receipt of a negative  
277 result) has a relative utility of 1.5 compared to a standard 10 day quarantine. Reducing  
278 the delay between test and result leads to a corresponding increase in utility: a rapid  
279 test ( $\Delta_T = 0$ ) on day six has a relative utility of 1.9 for an equivalent efficacy (Fig. 4B).

280 Finally, we consider the effects of reinforced prevention measures, where individ-  
281 uals who receive a negative test result are released from quarantine but must adhere  
282 to strict hygiene and social distancing protocols until the end of the full quarantine.  
283 Considering a 50% reduction of post-quarantine transmission, we see large increases  
284 in both efficacy and utility for early testing strategies, but with diminishing returns as  
285 the time at which tests are conducted is increased (dashed lines in Fig. 4). Note that  
286 we assume no contribution to the number of days spent in quarantine in the utility  
287 function due to mask wearing and social distancing in the post-release phase.

## 288 **Adherence to quarantine and proportion of individuals with persistently asymp-** 289 **tomatic infection**

290 Shortening the duration of quarantine from 10 days to five days would require more  
291 than twice as many individuals to adhere to the quarantine guidelines in order to  
292 maintain the same overall efficacy (Fig. 5A). If quarantine is shortened further, then  
293 the required increase in adherence grows rapidly and soon becomes unfeasible (the  
294 maximum possible adherence is  $\alpha = 1$ , so depending on the baseline level of adher-  
295 ence it may be impossible to increase this by the required factor). Hence the argument  
296 of shortening quarantine to increase adherence is of limited use.

297 As a final consideration, we note that our quantification of the fraction of trans-  
298 mission prevented by quarantine [Eq. (1)] is more relevant to individuals with per-  
299 sistent asymptomatic SARS-CoV-2 infection than to those who develop symptoms  
300 during the quarantine phase and are subsequently tested and isolated. The fraction  
301 of transmission prevented by quarantine is an increasing function of the fraction of  
302 asymptomatic cases (Fig. 5B). This means that we likely overestimate the efficacy of



**Fig. 5** A) The change in adherence  $\alpha$  needed to maintain quarantine efficacy of the  $n = 10$  day strategy if we change the quarantine duration to  $n'$  days (x-axis), i.e.  $\alpha(n')/\alpha(10)$  [Eq. (6)]. B) The impact of symptomatic cases on the fraction of total onward transmission per infected traced contact that is prevented by quarantine [Eq. (7)]. We fix  $\Delta_Q = 3$  as the delay until quarantine, and  $t_S = 5$ , which is the mean incubation time. The curve for  $a = 1$  corresponds to Fig. 3A. In both panels we use  $t_E = 0$ , which is the mean infection time of secondary cases based on the infectivity profile.

303 quarantine as we are also counting transmission that is prevented by isolation follow-  
 304 ing a positive test result.


### 305 3.2 Quarantine of returning travellers

306 Returning travellers that have been infected on a short journey will have, on average,  
 307 used up less of their infectivity potential by the time they return than a traveller who  
 308 was infected on a long journey. Hence, the *total* transmission that can be prevented  
 309 by a long quarantine period (i.e. 10 days) upon arrival, is greater for short trips (Fig.  
 310 S1). When considering the fraction of *local* transmission that can be prevented by  
 311 quarantine [ $F_{\text{local}}$ ; Eq. (2)], then shorter quarantine durations have a greater impact  
 312 on long than short trips (Fig. 6A). Again, this is because, on average, the traveller on  
 313 a long trip would have been exposed earlier and they will be infectious for a shorter  
 314 time period after arrival. A standard quarantine duration of 10 days is enough to  
 315 prevent almost all local transmission for any travel duration (Fig. 6A).

316 The human cost of quarantine here is  $n$  days, and hence the utility is simply  
 317  $U(n) = sF_{\text{local}}(n)/n$ . Comparing two different strategies  $n$  and  $n'$ , we have the rel-  
 318 ative utility

$$\frac{U(n')}{U(n)} = \frac{n'F_{\text{local}}(n)}{nF_{\text{local}}(n')}. \quad (10)$$

319 As above, an individual who has been infected during a long trip will have, on av-



**Fig. 6** A) The fraction of local onward transmission per quarantined traveller that is prevented by quarantine [ $F_{\text{local}}$ ; Eq. (2)]. B) The relative utility of different quarantine strategies (x-axis) compared to  $n = 10$  days, i.e.  $U(n')/U(10)$  [Eq. (10)]. Colours represent the duration of travel  $y$  and we assume infection can occur on any day  $-y \leq t_E \leq 0$  with uniform probability.


320 erage, been infected earlier and therefore will have, on average, less remaining infec-  
 321 tivity potential upon return compared with an individual who travelled for a short  
 322 duration. Hence, if an individual traveller is to be quarantined, then the optimum du-  
 323 ration of quarantine, based on this metric of utility, would depend on the duration of  
 324 their travel, with shorter journeys requiring longer quarantine (Fig. 6B). This might be  
 325 counter-intuitive because individuals who have been on longer journeys to high risk  
 326 countries have a higher probability of being infected. The absolute utility  $U$  of quar-  
 327 antining such individuals is indeed higher than for individuals returning from shorter  
 328 journeys. However, here, we are not considering the question of whether to quaran-  
 329 tine or not, but we are assuming that the individual is quarantined and are trying  
 330 to optimise the duration of quarantine in response to the expected infection dynam-  
 331 ics. As the relative utility [Eq. (10)] is independent of  $s$ , the prevalence of disease in  
 332 the travel destination (which should correlate with the fraction of travellers becoming  
 333 infected at that destination) does not influence the optimal quarantine duration.

### 334 Test-and-release strategy

335 If a returning traveller is tested at time  $t_T = x$  during quarantine then they are released  
 336 on day  $t_{R^-} = x + \Delta_T$  if the test is negative, or else kept in quarantine until day  $t_{R^+} = n$ .  
 337 We focus on a seven day trip and fix  $n = 10$  days, which is long enough to prevent  
 338 almost 100% of local onward transmission from the returning traveller (Fig. 6A). The  
 339 fraction of local transmission prevented by testing-and-releasing an infected traveller  
 340 accounts for false-negative test results.

341 As was the case for the traced contacts, the fraction of local transmission prevented  
 342 by standard quarantine bounds the efficacy of the test-and-release quarantine strat-  
 343 egy (Fig. 7A). The timing of the test can have significant impact on prevented trans-  
 344 mission; late testing reduces the false negative probability but increases the stay in  
 345 quarantine. An important consequence of this is that testing on arrival ( $x = 0$ ) is  
 346 a poor strategy for limiting transmission: testing upon return at day zero only pre-  
 347 vents 54.1% of local transmission, but testing on day five and releasing on day seven  
 348 prevents 98.5% of local transmission.

349 A rapid test could eliminate the two-day delay between test and result. If the rapid  
 350 test ( $\Delta_t = 0$ ) has the same sensitivity and specificity as the laboratory-based RT-PCR  
 351 test, then the duration of quarantine of individuals with a negative test result can be  
 352 shortened by one day with minimal loss in efficacy compared to the standard test (Fig.  
 353 7A).



**Fig. 7** A) The impact of test-and-release for quarantined travellers, in terms of what fraction of local onward transmission per quarantined infected traveller is prevented by quarantine. The grey lines represent the upper and lower bounds for the fraction of transmission that can be prevented by quarantine without testing. B) The relative utility of different test-and-release quarantine durations compared to standard quarantine with duration  $n = 10$  days. The grey curve is the relative utility of standard quarantine without testing. In both panels we consider a travel duration of  $y = 7$  days and we assume infection can occur on any day  $-y \leq t_E \leq 0$  with uniform probability. Individuals are tested on day  $x$  after returning on day 0 and released on day  $x + \Delta_T$  ( $x$ -axis) if negative (colour corresponds to  $\Delta_T$ ). We assume that the fraction of individuals in quarantine that are infected is  $s = 0.1$ , and that there are no false-positive test results. Dashed lines in both panels assume the released travellers have a 50% reduced transmission ( $r = 0.5$ ) due to extra hygiene and social distancing measures imposed by reduced quarantine [Eq. (4)].

354 Fig. 7A describes the epidemiological effect of quarantining individuals. The average  
 355 duration of quarantine will be  $\langle x + \Delta_T + s[1 - f(x - t_E)](n - x - \Delta_T) \rangle_y$ , and hence  
 356 the utility  $U_{\text{test}}(n, x)$  and relative utility  $U_{\text{test}}(n', x)/U(n)$  will depend on  $s$ . Early test-

357 ing greatly reduces the average duration of quarantine and hence leads to increased  
358 utility (Fig. 7B). Enforcing additional hygiene and social distancing guidelines follow-  
359 ing a negative test and release can increase both efficacy and utility for early testing  
360 strategies, but with diminishing returns as the release date is increased (dashed lines  
361 in Fig. 7).

362 We note that the relative utility of the test-and-release strategy depends on the  
363 fraction of individuals in quarantine that are infected ( $s$ ), and this fraction may change  
364 depending on disease prevalence at the travel destination and the duration of travel.  
365 E.g., the infected fraction of travellers returning from a long stay in a high-risk country  
366 is likely to be higher than the infected fraction of travellers returning from a short stay  
367 to a low risk country. In Fig. 7B we keep  $s$  fixed.

368 Finally, we note that the change in adherence required to balance a change in ef-  
369 ficacy for shortened quarantine durations is dependent on the travel duration, with  
370 short travel durations requiring a greater increase in adherence compared with longer  
371 travel durations (Fig. S2A).

## 372 4 Discussion

373 Quarantine is one of the most important measures in controlling the ongoing SARS-  
374 CoV-2 epidemic due to the large fraction of presymptomatic and asymptomatic trans-  
375 mission. A quarantine period of 10 days from exposure, as currently implemented  
376 in Switzerland, is long enough to prevent almost all onward transmission from in-  
377 fected contacts of confirmed cases from the point of entering quarantine: increasing  
378 the duration of quarantine beyond 10 days has no extra benefit. Reducing the delay  
379 to quarantining individuals increases the fraction of total transmission that is pre-  
380 ventable. The same 10 day quarantine duration will prevent almost all local onward  
381 transmission from infected travel returners from the time of arrival, independent of  
382 their travel duration.

383 Any decrease in the duration of quarantine of an infected individual will result in  
384 increased onward transmission. Furthermore, our analyses suggest that this increase  
385 in transmission cannot realistically be compensated by increased adherence for signif-  
386 icantly shortened quarantine (fewer than five days). However, there are diminishing  
387 returns for each day that we add to quarantine: increasing the duration from 10 days  
388 has a negligible effect in terms of reduced transmission. One therefore has to assess  
389 how much human cost, measured in terms of days spent in quarantine, we are will-  
390 ing to spend to prevent disease transmission. By comparing the ratio of prevented  
391 transmission to quarantine duration, we have shown that maximal utility strategies  
392 can exist. This ratio is maximised for quarantine durations of six to eight days after  
393 exposure for traced contacts, and potentially less for returning travellers depending

394 on their duration of travel. Importantly, under this metric the fraction of individu-  
395 als in quarantine that are infected does not affect the optimal duration of quarantine.  
396 Therefore, the argument that we should shorten quarantine because of the low proba-  
397 bility of being infected is misguided under our definition of utility and in the absence  
398 of testing during quarantine.

399 A test-and-release strategy will lead to a lower average quarantine duration across  
400 infected and non-infected individuals. However, due to the considerable false-negative  
401 probability of the RT-PCR test (Kucirka et al., 2020), this strategy also leads to in-  
402 creased transmission as infectious individuals are prematurely released. Neverthe-  
403 less, test-and-release strategies prevent more transmission than releasing without test-  
404 ing, and hence test-and-release increases the utility of quarantine. Reducing the delay  
405 between test and result leads to further reduced transmission and increased utility,  
406 and reinforcing individual prevention measures after release is also effective for short  
407 quarantine periods.

408 The ratio of transmission prevented versus days spent in quarantine is only one  
409 possible definition of utility. Defining the appropriate function is ultimately a policy  
410 question: the economical, societal, and individual costs are likely a function the days  
411 spent in quarantine, but we cannot determine the shape of this function. Another  
412 perspective is that the utility of preventing transmission is crucially dependent on  
413 whether it brings the effective reproductive number under one.

414 Ultimately, bringing the reproductive number below one requires a combination  
415 of effective measures including isolation, physical distancing, hygiene, contact trac-  
416 ing, and quarantine (Kucharski et al., 2020). Effective quarantine is only possible in  
417 the presence of efficient contact tracing to find the potentially exposed individuals in  
418 a short time, as well as surveillance of disease prevalence to identify high-risk travel.  
419 Further reducing the time taken to quarantine a contact after exposure and reduc-  
420 ing the delay between test and result will allow average quarantine durations to be  
421 shorter, which increases the benefit to cost ratio of quarantine.

422 The scenarios of returning travellers and traced contacts of confirmed SARS-CoV-2  
423 cases differ in the probability of having been exposed and infected and on the infor-  
424 mation available about the likely window of exposure. The impact of quarantining  
425 returning travellers depends on the duration of travel, and whether we consider the  
426 local prevention of transmission or the total transmission prevented by quarantine.  
427 However, a single test done immediately after return can only prevent a small frac-  
428 tion of the transmission from a returning traveller because of the false-negative rate  
429 of the RT-PCR test early in infection. Therefore testing should be postponed until as  
430 late as possible, and utilising rapid tests could be crucial if their performance char-  
431 acteristics are acceptable. This same principle also applies to traced contacts. Our  
432 findings are aligned with those of two recent simulation studies which estimate the


433 role that quarantine plays in limiting transmission from returning travellers (Clifford  
434 et al., 2020) and from traced contacts (Quilty et al., 2020b).

435 Our results are based on the latest estimates of the generation time distribution  
436 of COVID-19 (Ferretti et al., 2020a). Potential limitations to our approach could be  
437 that these distributions may change throughout the epidemic, particularly depending  
438 on how people respond to symptoms (Ali et al., 2020). Furthermore, these distribu-  
439 tions could be different between persistently asymptomatic and symptomatic individ-  
440 uals (Buitrago-Garcia et al., 2020). For travellers, another consideration is that lengthy  
441 quarantine is seen as a deterrent to travel to high risk areas (IATA, 2020). Any short-  
442 ening of quarantine may lead to an increase in travel volume, potentially leading to a  
443 compounded increase in disease transmission.


444 In the absence of empirical data about the effectiveness of different durations of  
445 quarantine, mathematical modelling can be used objectively to explore the fraction  
446 of onward transmission by infected contacts or returning travellers that can be pre-  
447 vented. However, determining the optimal quarantine strategy to implement depends  
448 on the impact that shortening the duration of quarantine has on individuals, society,  
449 and the economy, versus how much weight is assigned to a consequential increase  
450 in transmission. Both the individual, societal and economic impact, as well as the  
451 weight of transmission increase, will have to be considered based on the current epi-  
452 demiological situation. We have shown that there are quarantine strategies based on a  
453 test-and-release protocol that, from an epidemiological viewpoint, perform almost as  
454 well as the standard 10 day quarantine, but with a lower cost in terms of person days  
455 spent in quarantine. This applies to both travellers and contacts, but the specifics de-  
456 pend on the context.

457

## Supplemental figures



**Fig. S1** Total transmission prevented in returning travellers. A) The fraction of total on-ward transmission per quarantined traveller that is prevented by quarantine [ $F$ ; Eq. (1)]. B) The relative utility of different quarantine strategies ( $x$ -axis) compared to  $n = 10$  days, i.e.  $U(n')/U(10)$  [Eq. (10)]. Colours represent the duration of travel  $y$  and we assume infection can occur on any day  $-y \leq t_E \leq 0$  with uniform probability.



**Fig. S2** Adherence and symptoms for returning travellers. A) The change in adherence needed to maintain quarantine efficacy of the  $n = 10$  day strategy if we change the quarantine duration to  $n'$  days (x-axis), i.e.  $\alpha(n')/\alpha(10) = F_{\text{local}}(10)/F_{\text{local}}(n')$ . B) The impact of symptomatic cases on the fraction of total onward transmission per quarantined traveller that is prevented by quarantine. We fix the travel duration to  $y = 7$  days and assume  $t_E$  is uniformly distributed between  $-y$  and 0. The curve  $a = 1$  corresponds to Fig. 6. We use the mean incubation time of five days, such that  $t_S = t_E + 5$ .

## References

458

459 Ali, S. T., et al. (2020). Serial Interval of SARS-CoV-2 Was Shortened over Time by  
460 Nonpharmaceutical Interventions. *Science*, 369(6507), 1106–1109, <https://doi.org/10.1126/science.abc9004>.  
461

462 Ashcroft, P., Huisman, J. S., Lehtinen, S., Bouman, J. A., Althaus, C. L., Regoes, R. R., &  
463 Bonhoeffer, S. (2020). COVID-19 Infectivity Profile Correction. *Swiss Medical Weekly*,  
464 150, w20336, <https://doi.org/10.4414/smw.2020.20336>.

465 Brooks, S. K., Webster, R. K., Smith, L. E., Woodland, L., Wessely, S., Greenberg, N., &  
466 Rubin, G. J. (2020). The Psychological Impact of Quarantine and How to Reduce It:  
467 Rapid Review of the Evidence. *The Lancet*, 395(10227), 912–920, [https://doi.org/10.1016/S0140-6736\(20\)30460-8](https://doi.org/10.1016/S0140-6736(20)30460-8).  
468

469 Buitrago-Garcia, D., et al. (2020). Occurrence and Transmission Potential of Asymp-  
470 tomatic and Presymptomatic SARS-CoV-2 Infections: A Living Systematic Review  
471 and Meta-Analysis. *PLOS Medicine*, 17(9), e1003346, <https://doi.org/10.1371/journal.pmed.1003346>.  
472

473 Cheng, H.-Y., Jian, S.-W., Liu, D.-P., Ng, T.-C., Huang, W.-T., Lin, H.-H., & for the Tai-  
474 wan COVID-19 Outbreak Investigation Team (2020). Contact Tracing Assessment  
475 of COVID-19 Transmission Dynamics in Taiwan and Risk at Different Exposure Pe-  
476 riods before and after Symptom Onset. *JAMA Internal Medicine*, 180(9), 1156–1163,  
477 <https://doi.org/10.1001/jamainternmed.2020.2020>.

- 478 Clifford, S., et al. (2020). Strategies to Reduce the Risk of SARS-CoV-2 Re-Introduction  
479 from International Travellers. *medRxiv*, (pp. 2020.07.24.20161281), [https://doi.org/](https://doi.org/10.1101/2020.07.24.20161281)  
480 [10.1101/2020.07.24.20161281](https://doi.org/10.1101/2020.07.24.20161281).
- 481 Ferretti, L., et al. (2020a). The Timing of COVID-19 Transmission. *medRxiv*, (pp.  
482 2020.09.04.20188516), <https://doi.org/10.1101/2020.09.04.20188516>.
- 483 Ferretti, L., et al. (2020b). Quantifying SARS-CoV-2 Transmission Suggests Epidemic  
484 Control with Digital Contact Tracing. *Science*, 368(6491), [https://doi.org/10.1126/](https://doi.org/10.1126/science.abb6936)  
485 [science.abb6936](https://doi.org/10.1126/science.abb6936).
- 486 Gostic, K., Gomez, A. C., Mummah, R. O., Kucharski, A. J., & Lloyd-Smith, J. O. (2020).  
487 Estimated Effectiveness of Symptom and Risk Screening to Prevent the Spread of  
488 COVID-19. *eLife*, 9, e55570, <https://doi.org/10.7554/eLife.55570>.
- 489 Grantz, K. H., Lee, E. C., McGowan, L. D., Lee, K. H., Metcalf, C. J. E., Gurley, E. S.,  
490 & Lessler, J. (2020). Maximizing and Evaluating the Impact of Test-Trace-Isolate  
491 Programs. *medRxiv*, (pp. 2020.09.02.20186916), [https://doi.org/10.1101/2020.09.](https://doi.org/10.1101/2020.09.02.20186916)  
492 [02.20186916](https://doi.org/10.1101/2020.09.02.20186916).
- 493 Guglielmi, G. (2020). Fast Coronavirus Tests: What They Can and Can't Do. *Nature*,  
494 585(7826), 496–498, <https://doi.org/10.1038/d41586-020-02661-2>.
- 495 He, X., et al. (2020). Temporal Dynamics in Viral Shedding and Transmissi-  
496 bility of COVID-19. *Nature Medicine*, 26(5), 672–675, [https://doi.org/10.1038/](https://doi.org/10.1038/s41591-020-0869-5)  
497 [s41591-020-0869-5](https://doi.org/10.1038/s41591-020-0869-5).
- 498 IATA (2020). Traveler Survey Reveals COVID-19 Concerns.  
499 <https://www.iata.org/en/pressroom/pr/2020-07-07-01/>.
- 500 Kucharski, A. J., et al. (2020). Effectiveness of Isolation, Testing, Contact Tracing, and  
501 Physical Distancing on Reducing Transmission of SARS-CoV-2 in Different Settings:  
502 A Mathematical Modelling Study. *The Lancet Infectious Diseases*, 20(10), 1151–1160,  
503 [https://doi.org/10.1016/S1473-3099\(20\)30457-6](https://doi.org/10.1016/S1473-3099(20)30457-6).
- 504 Kucirka, L. M., Lauer, S. A., Laeyendecker, O., Boon, D., & Lessler, J. (2020). Variation  
505 in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction–Based  
506 SARS-CoV-2 Tests by Time since Exposure. *Annals of Internal Medicine*, 173(4), 262–  
507 267, <https://doi.org/10.7326/M20-1495>.
- 508 Lehtinen, S., Ashcroft, P., & Bonhoeffer, S. (2020). On the Relationship be-  
509 tween Serial Interval, Infectiousness Profile and Generation Time. *medRxiv*, (pp.  
510 2020.09.18.20197210), <https://doi.org/10.1101/2020.09.18.20197210>.
- 511 Li, Q., et al. (2020). Early Transmission Dynamics in Wuhan, China, of Novel Coro-  
512 navirus–Infected Pneumonia. *New England Journal of Medicine*, 382, 1199–1207,  
513 <https://doi.org/10.1056/NEJMoa2001316>.
- 514 Nicola, M., et al. (2020). The Socio-Economic Implications of the Coronavirus Pan-  
515 demic (COVID-19): A Review. *International Journal of Surgery*, 78, 185–193, <https://doi.org/10.1016/j.ijssu.2020.04.018>.
- 516

- 517 Nussbaumer-Streit, B., et al. (2020). Quarantine Alone or in Combination with Other  
518 Public Health Measures to Control COVID-19: A Rapid Review. *Cochrane Database*  
519 *of Systematic Reviews*, (9), <https://doi.org/10.1002/14651858.CD013574.pub2>.
- 520 Parmet, W. E. & Sinha, M. S. (2020). Covid-19 — The Law and Limits of Quar-  
521 antine. *New England Journal of Medicine*, 382(15), e28, [https://doi.org/10.1056/](https://doi.org/10.1056/NEJMp2004211)  
522 [NEJMp2004211](https://doi.org/10.1056/NEJMp2004211).
- 523 Quilty, B. J., Clifford, S., CMMID nCoV working group, Flasche, S., & Eggo, R. M.  
524 (2020a). Effectiveness of Airport Screening at Detecting Travellers Infected with  
525 Novel Coronavirus (2019-nCoV). *Eurosurveillance*, 25(5), 2000080, [https://doi.org/](https://doi.org/10.2807/1560-7917.ES.2020.25.5.2000080)  
526 [10.2807/1560-7917.ES.2020.25.5.2000080](https://doi.org/10.2807/1560-7917.ES.2020.25.5.2000080).
- 527 Quilty, B. J., Clifford, S., Flasche, S., Kucharski, A. J., CMMID COVID-19 Working  
528 Group, & Edmunds, W. J. (2020b). Quarantine and Testing Strategies in Contact  
529 Tracing for SARS-CoV-2. *medRxiv*, (pp. 2020.08.21.20177808), [https://doi.org/10.](https://doi.org/10.1101/2020.08.21.20177808)  
530 [1101/2020.08.21.20177808](https://doi.org/10.1101/2020.08.21.20177808).
- 531 WHO (2020). Considerations for Quarantine of Contacts of COVID-19 Cases.  
532 *WHO/2019-nCoV/IHR\_Quarantine/2020.3*.
- 533 Xia, W., et al. (2020). Transmission of Corona Virus Disease 2019 during the Incubation  
534 Period May Lead to a Quarantine Loophole. *medRxiv*, (pp. 2020.03.06.20031955),  
535 <https://doi.org/10.1101/2020.03.06.20031955>.